# IceCure Medical (ICCM) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/ICCM
## Company Profile
- Ticker: ICCM
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Israel
- Tags: MedTech, Oncology
## Stock Data
- Close: 3.105 USD
- Market cap: 11292054.061 USD
- Last updated: 2026-08-12
## Business Overview
### Cryoablation Medical Technology
IceCure Medical develops minimally invasive systems that destroy tumors by freezing them as an alternative to surgical removal.
### ProSense
The ProSense system uses liquid nitrogen-based probes to create a controlled ice ball around a tumor under image guidance.
### Breast Cancer Commercialization
FDA clearance supports use in selected early-stage breast cancer patients, providing the foundation for expanded U.S. installations and disposable probe utilization.
### Broader Tumor Applications
The platform is also used or studied in kidney, liver, lung, and other tumors accessible to percutaneous cryoablation.
## Why The Stock Is Moving

The latest monitored company update is “IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation.” The corresponding closing-price reaction is not yet available.

## Future Catalysts

- The cleaner way to frame IceCure Medical right now is around its latest development priorities. The most useful line from the latest update is and North America May 12, 2026 8:30 am EDT Download as PDF Pent-up demand immediately following FDA clearance generates 46% increase in active customer accounts using ProSense® as.... That should keep the program at the center of the company narrative for now.

## Recent News
- 2026-08-13 13:10 EST — [IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation](https://biopharmsignal.com/news/ICCM/icecure-highlights-two-new-peer-reviewed-publications-supporting-cryoablation-in-d4db1bc0) — Source: IceCure Medical
- 2026-08-12 12:30 EST — [IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year](https://biopharmsignal.com/news/ICCM/icecure-reports-its-financial-results-for-the-first-half-of-2026-with-45-revenue-00c0201f) — Source: IceCure Medical
- 2026-08-06 12:05 EST — [IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment](https://biopharmsignal.com/news/ICCM/icecure-medical-adds-adventist-health-as-u-s-clinical-site-for-its-post-marketin-442281ef) — Source: IceCure Medical
- 2026-08-05 12:30 EST — [IceCure Medical to Report First Half 2026 Financial and Operating Results on August 12, 2026](https://biopharmsignal.com/news/ICCM/icecure-medical-to-report-first-half-2026-financial-and-operating-results-on-aug-a71aaf99) — Source: IceCure Medical
- 2026-07-29 12:25 EST — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3) — Source: IceCure Medical